A5066505961- Multiple Myeloma Research and Treatments
- Retinal Imaging and Analysis
- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Ocular Surface and Contact Lens
- Corneal Surgery and Treatments
- Retinal and Macular Surgery
- Protein Degradation and Inhibitors
- Retinoids in leukemia and cellular processes
- Ocular Infections and Treatments
- Advanced Breast Cancer Therapies
- Research on Leishmaniasis Studies
- PI3K/AKT/mTOR signaling in cancer
- Atrial Fibrillation Management and Outcomes
- Statistical Methods in Clinical Trials
- Cardiac electrophysiology and arrhythmias
- Drug-Induced Ocular Toxicity
- Ocular and Laser Science Research
- Cardiac Arrhythmias and Treatments
- Cardiac Arrest and Resuscitation
- Ocular Diseases and Behçet’s Syndrome
- Glaucoma and retinal disorders
- Angiogenesis and VEGF in Cancer
- Intraocular Surgery and Lenses
- Ocular Disorders and Treatments
University of Rochester Medical Center
2016-2024
University of Rochester
2009-2023
Crozer-Keystone Health System
2019
Cold Spring Harbor Laboratory
2015
Rocky Mountain MS Center
2003
University of Colorado Health
2001
Denver Health Medical Center
2001
University of Colorado Denver
2001
Allegheny College
1998
Mount Sinai Beth Israel
1996
We have recently recapitulated metastasis of human PTEN/TP53-mutant prostate cancer in the mouse using RapidCaP system. Surprisingly, we found that this is driven by MYC, and not AKT, activation. Here, show cell-cell communication IL6 drives AKT-MYC switch through activation AKT-suppressing phosphatase PHLPP2, when PTEN p53 are lost together, but separately. then communicates a downstream program STAT3-mediated MYC activation, which cell proliferation. Similarly, tissues, peak proliferation...
Clinical trials in neovascular age-related macular degeneration (nAMD) demonstrate that high visual acuity (VA) can be maintained, and low VA improved with anti-vascular endothelial growth factor (VEGF) treatment. Few real-world data investigating the relationship between baseline long-term outcomes exist. This study compares at diagnosis after treatment using from a large patient registry.Retrospective of IRIS Registry patients diagnosed nAMD one or both eyes January 2013 June 2017....
Introduction Newer treatment options for relapsed/refractory multiple myeloma (RRMM) with efficacy and safety profiles that differ from traditional therapies have facilitated personalized management strategies to optimize patient outcomes. In the context of such management, understanding how characteristics influence patients’ preferences is essential. This study assessed RRMM attributes determined trade-offs between potential benefits, administration procedures, adverse effects. Methods...
Antibody-drug conjugates (ADCs) are a relatively recent advance in the delivery of chemotherapeutics that improve targeting cytotoxic agents. However, despite their antitumor activity, severe ocular adverse effects, including vision loss, have been reported for several ADCs. The nonspecific uptake ADCs into human corneal epithelial cells (HCECs) and precursors via macropinocytosis has proposed to be primary mechanism toxicity. In this study, we evaluated ability novel polymer,...
Purpose: To evaluate the effectiveness of glycerin 1% formulated with novel and proprietary ophthalmic excipient poly(l-lysine)–graft–poly(ethylene glycol) (PLL-g-PEG) (Eyeon Particle Sciences LLC) in extending tear film break-up time (TFBUT) compared a market-leading artificial formulation propylene glycol (0.3%) polyethylene (0.4%) (Systane® Lubricant Eye Drops; Alcon, Fort Worth, TX). Methods: This prospective single-center, single visit, randomized, double-masked exploratory trial new...
Microcirculation (2010) 17, 1–9. doi: 10.1111/j.1549-8719.2009.00012.x Objective: To test the hypothesis that rapamycin inhibits induced microvascular hyperpermeability directly in vivo. Methods: Male golden Syrian hamsters (80–120 g) were treated with either (at 0.1, 0.5, 2, and 10 mg/kg i.p.) or vehicle at 24 hours 1 hour prior to preparation of cheek pouch. Caveolin-1 scaffolding (1 mg/kg; positive inhibitory control) was injected i.p. experiment. 10−8 M vascular endothelial growth factor...
High altitude retinal hemorrhages are commonly seen at altitudes above 4270 m. While these generally asymptomatic, macular involvement may result in permanent visual acuity deficit. We present the case of a 29-year-old male recreational skier who traveled to ski resort 2930 m, ascended 3470 and developed acute mountain sickness, high pulmonary edema, bilateral hemorrhages. A funduscopic examination determine if hemorrhage is be performed by clinicians final assessment patients following illness.
In the randomized phase II DREAMM-2 study, single-agent belantamab mafodotin demonstrated deep and durable responses a manageable safety profile in triple-class refractory relapsed/refractory multiple myeloma (RRMM). We present patient-reported outcomes (PROs) from this study for patients treated with approved dose of (2.5 mg/kg q3w). Disease treatment-related symptoms, health-related quality life (HRQOL), functioning, ocular changes were assessed using questionnaires (European Organisation...
TPS8073 Background: Belantamab mafodotin (belamaf: BLENREP) is a first-in-class, monomethyl auristatin F (MMAF)-containing, B-cell maturation antigen (BCMA)-directed antibody–drug conjugate (ADC). In the DREAMM-2 study, belamaf showed deep responses with manageable safety profile in patients relapsed/refractory multiple myeloma (RRMM). At 13 months of follow-up, median duration response was 11 and overall survival 13.7 at 2.5 mg/kg Q3W dose. Corneal events are common expected other...
In a patient with Wolff-Parkinson-White syndrome and right inferoseptal accessory pathway who had previously unsuccessful surgical attempt at ablation, the was found to be adjacent branch of coronary sinus. Radiofrequency energy delivered within this ablate successfully. This demonstrates an alternative approach more common method radiofrequency ablation pathways from tricuspid or mitral annular location.
e20046 Background: A prior retrospective analysis of US patients (pts) with RRMM suggested that pts treated belamaf, a BCMA-targeting antibody-drug conjugate, experienced similar outcomes to those who received belamaf in the pivotal DREAMM-2 study. This updated aimed characterize pts, assess occurrence and management ocular adverse events (AEs), evaluate effectiveness real-world setting. Methods: retrospective, longitudinal, observational study used data sourced from EHR-derived Flatiron...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: A prior retrospective analysis of US patients with relapsed/refractory multiple myeloma (RRMM) suggested that treated belantamab mafodotin (belamaf), a B-cell maturation antigen-targeting antibody-drug conjugate, experienced similar outcomes to those who received belamaf in the pivotal DREAMM-2 study. Aims: This updated aimed characterize patients, assess occurrence management ocular adverse events (AEs), evaluate...